FIELD: medicine.
SUBSTANCE: agent contains riboflavin mononucleotide, hydroxypropyl methylcellulose, sodium chloride, tris-(hydroxymethyl)-methylamine, Nipagin, Trilon B in a certain ratio, wt %: 0.24-0.26, 0.4-0.6, 0.8-0.9, 0.08-0.12, 0.0075-0.0125, 0.005-0.01 and purified distilled water up to 100 respectively.
EFFECT: using the invention enables increasing the transepithelial penetration of riboflavin ensured by increasing its concentration, and preventing the corneal thinning.
1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| OPHTHALMOLOGICAL MEANS FOR ULTRAVIOLET CORNEAL CROSSLINKING | 2016 |
|
RU2646452C1 |
| HYPOSMOTIC OPHTHALMIC MEANS FOR ULTRAVIOLET CROSSLINKING OF THIN CORNEAS | 2016 |
|
RU2631604C1 |
| CROSS-LINKING OPHTHALMIC AGENT | 2009 |
|
RU2412707C1 |
| OPHTHALMIC CROSS-LINKING AGENT-2 | 2012 |
|
RU2475248C1 |
| METHOD OF TREATMENT OF KERATECTASIA BY THE METHOD OF PULSE ACCELERATED ULTRAVIOLET CROSSLINKING OF CORNEA | 2017 |
|
RU2682494C1 |
| METHOD OF CORNEAL GRAFT PREPARATION FOR LAYER-BY-LAYER KERATOPLASTY | 2019 |
|
RU2723135C1 |
| METHOD OF TREATING EPITHELIAL-ENDOTHELIAL CORNEAL DYSTROPHY | 2019 |
|
RU2703361C1 |
| COMBINED METHOD FOR THE TREATMENT OF CORNEAL DISEASES WITH THE USE OF KERATOPLASTY AND CROSS-LINKING | 2017 |
|
RU2676434C1 |
| METHOD OF TREATING HERPETIC KERATITIS | 2013 |
|
RU2531426C1 |
| METHOD OF TREATING KERATOCONUS STAGE I-II | 2022 |
|
RU2819801C2 |
